Literature DB >> 9299380

Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro.

E Gilad1, B Zingarelli, A L Salzman, C Szabó.   

Abstract

Peroxynitrite and hydroxyl radical are reactive oxidants produced during myocardial reperfusion injury. In various cell types, including macrophages and smooth muscle cells, peroxynitrite and hydrogen peroxide cause DNA single strand breakage, which triggers the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS), resulting in cytotoxicity. Using 3-aminobenzamide and nicotinamide, inhibitors of PARS, we investigated the role of PARS in the pathogenesis of myocardial oxidant injury in H9c2 cardiac myoblasts in vitro. Peroxynitrite (100-1000 microM), hydrogen peroxide (0.3-10 microM) and the NO donor compounds S-nitroso-N-accetyl-DL-penicillamine (SNAP) and diethyltriamine NONOate all caused a dose-dependent reduction of the mitochondrial respiration of the cells, as measured by the mitochondrial-dependent conversion of MTT to formazan. Peroxynitrite and hydrogen peroxide, but not the NO donors caused activation of cellular PARS activity. The suppression of mitochondrial respiration by peroxynitrite and hydrogen peroxide, but not by the NO donors, was ameliorated by pharmacological inhibition of PARS. The protection by the PARS inhibitors diminished at extremely high concentrations of the oxidants. Hypoxia (1 h) followed by reoxygenation (1-24 h) also resulted in a significant activation of PARS, and caused a suppression of mitochondrial respiration, which was prevented by inhibition of PARS. Similar to the results obtained with the pharmacological inhibitors of PARS, a fibroblast cell line which derives from the PARS knockout mouse was protected against the suppression of mitochondrial respiration in response to peroxynitrite and reoxygenation, but not to NO donors, when compared to the result of cells derived from wild-type animals. Based on our data, we suggest that activation of PARS plays a role in the myocardial oxidant injury. Copyright 1997 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299380     DOI: 10.1006/jmcc.1997.0496

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  20 in total

1.  Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.

Authors:  Emese Tóth-Zsámboki; Eszter Horváth; Katarina Vargova; Eszter Pankotai; Kanneganti Murthy; Zsuzsanna Zsengellér; Tamás Bárány; Tamás Pék; Katalin Fekete; Róbert Gábor Kiss; István Préda; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

2.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

3.  An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart.

Authors:  J C Docherty; B Kuzio; J A Silvester; J Bowes; C Thiemermann
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 4.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

5.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

6.  Novel modulators of poly(ADP-ribose) polymerase.

Authors:  Csaba Szabo; Pal Pacher; Raymond A Swanson
Journal:  Trends Pharmacol Sci       Date:  2006-10-19       Impact factor: 14.819

Review 7.  Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).

Authors:  Badar Ul Islam; Safia Habib; Parvez Ahmad; Shaziya Allarakha; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2015-01-20

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  Hsp70 attenuates hypoxia/reoxygenation-induced activation of poly(ADP-ribose) synthetase in the nucleus of adult rat cardiomyocytes.

Authors:  Kouichi Tanonaka; Wakako Toga; Masaya Takahashi; Ken-ichiro Kawana; Yuki Miyamoto; Hiroyuki Yoshida; Satoshi Takeo
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

Review 10.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.